Company intelligence / Profile preview

Cenomed BioSciences

California, United Statesbiospace.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Cenomed BioSciences was focused on developing small molecule therapeutics targeting central nervous system disorders such as schizophrenia, Alzheimer's disease, mild cognitive impairment, ADHD, pain syndromes related to neurology/aging—and later pivoted some assets toward chemical defense applications. The company became a majority-owned subsidiary of Abraxis BioScience in the late 2000s. Its lead compounds included acetylcholinesterase inhibitors like phenserine and Posiphen. Several programs were discontinued or outlicensed after acquisition by Abraxis.

Therapeutic areas: PsychiatryNeurology
Modalities: Small moleculeAChE inhibitor
Industry: Biotech

Partnerships

Abraxis BioScienceThioPharmaTorreyPines Therapeutics

Beyond the preview

Go deeper on Cenomed BioSciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cenomed BioSciences.

Explore the full profile